• Mustapha Hajjou, Laura Krech, Christi Lane-Barlow, Lukas Roth, Victor S Pribluda, Souly Phanouvong, Latifa El-Hadri, Lawrence Evans, Christopher Raymond, Elaine Yuan, Lang Siv, Tuan-Anh Vuong, Kwasi Poku Boateng, Regina Okafor, Kennedy M Chibwe, and Patrick H Lukulay.
• Am. J. Trop. Med. Hyg. 2015 Jun 1; 92 (6 Suppl): 68-74.

AbstractMonitoring the quality of medicines plays a crucial role in an integrated medicines quality assurance system. In a publicly available medicines quality database (MQDB), the U.S. Pharmacopeial Convention (USP) reports results of data collected from medicines quality monitoring (MQM) activities spanning the period of 2003-2013 in 17 countries of Africa, Asia, and South America. The MQDB contains information on 15,063 samples collected and tested using Minilab® screening methods and/or pharmacopeial methods. Approximately 71% of the samples reported came from Asia, 23% from Africa, and 6% from South America. The samples collected and tested include mainly antibiotic, antimalarial, and antituberculosis medicines. A total of 848 samples, representing 5.6% of total samples, failed the quality test. The failure proportion per region was 11.5%, 10.4%, and 2.9% for South America, Africa, and Asia, respectively. Eighty-one counterfeit medicines were reported, 86.4% of which were found in Asia and 13.6% in Africa. Additional analysis of the data shows the distribution of poor-quality medicines per region and by therapeutic indication as well as possible trends of counterfeit medicines.© The American Society of Tropical Medicine and Hygiene.

17 keywords...

hide…